|
|
| | GSK 561679A Basic information |
| Product Name: | GSK 561679A | | Synonyms: | GSK 561679A;3-(4-Methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine;Verucerfont;CPD1230;GSK561679;NBI77860;CS-2618;Verucerfont,GSK561679 | | CAS: | 885220-61-1 | | MF: | C22H26N6O2 | | MW: | 406.48 | | EINECS: | | | Product Categories: | | | Mol File: | 885220-61-1.mol |  |
| | GSK 561679A Chemical Properties |
| density | 1.29 | | storage temp. | Store at -20°C | | solubility | DMSO : 86.7 mg/mL (213.29 mM) | | form | Solid | | pka | 4.78±0.40(Predicted) | | color | White to off-white |
| | GSK 561679A Usage And Synthesis |
| Uses | Verucerfont, is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. |
| | GSK 561679A Preparation Products And Raw materials |
|